EP Patent

EP0992245A1 — Radio-contrast agents

Assigned to Goldham Bioglan Pharma GmbH · Expires 2000-04-12 · 26y expired

What this patent protects

An imaging or contrast agent comprising a stereoisomer of a compound with at least one chiral centre, wherein said stereoisomer is in stereoisomeric excess and causes fewer adverse side effects on administration, or is less chemotoxic, than at least one other stereoisomer of said…

USPTO Abstract

An imaging or contrast agent comprising a stereoisomer of a compound with at least one chiral centre, wherein said stereoisomer is in stereoisomeric excess and causes fewer adverse side effects on administration, or is less chemotoxic, than at least one other stereoisomer of said chiral compound.

Drugs covered by this patent

Patent Metadata

Patent number
EP0992245A1
Jurisdiction
EP
Classification
—
Expires
2000-04-12
Drug substance claim
No
Drug product claim
No
Assignee
Goldham Bioglan Pharma GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.